Evidence mapPaperPMID 41516046Full record

ReviewInternational journal of molecular sciences2025

Leptin as a Potential Modifier of Neuroinflammation: Contrasting Roles in Alzheimer's Disease and Multiple Sclerosis.

Naghmeh Abbasi Kasbi, Barbara Elena Stopschinski, Alanna Gabrielle Polyak, Agastya Reddy Malladi, Navid Manouchehri, Philipp E Scherer, Olaf Stuve

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Naghmeh Abbasi KasbiDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Barbara Elena StopschinskiDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-5715-4567
Alanna Gabrielle PolyakDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Agastya Reddy MalladiDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Navid ManouchehriDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Philipp E SchererTouchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-0680-3392
Olaf StuveDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neuroendocrine and immune systems interact bidirectionally through shared ligands and receptors during inflammation, thereby regulating immune responses. Leptin, primarily known for its role in energy metabolism and appetite regulation, also modulates neuroinflammatory pathways. Its receptors are widely expressed on immune cells and contribute to immune mechanisms implicated in the pathogenesis of neuroinflammatory disorders such as multiple sclerosis (MS) and Alzheimer's disease (AD). This review highlights recent advances in understanding leptin's role in immune regulation, with a focus on its impact on MS and AD. A comprehensive literature review was conducted until October 2025, using PubMed, Google Scholar, and Scopus to identify studies investigating leptin in neuroinflammatory conditions, particularly MS and AD. Leptin exerts broad immunomodulatory effects by activating T cells, dendritic cells, and microglia, and promoting their proliferation and phagocytosis. Its elevation enhances Th1 and Th17 responses, drives pro-inflammatory macrophage phenotype polarization, and suppresses regulatory T cell and Th2 responses, immune pathways involved in MS. Peripheral leptin levels are increased in MS, especially during disease exacerbations. In contrast, in AD, they are typically reduced, particularly in patients with normal body mass index (BMI), where their decline contributes to amyloid-β and tau pathology. These divergent patterns position leptin as a bidirectional regulator at the intersection of immunity and neurodegeneration. Additionally, its protective or detrimental effects likely depend on whether it acts under physiological conditions or in the context of obesity-induced leptin resistance. Elevated leptin levels in obesity exacerbate inflammation and diminish its neuroprotective effects. In conclusion, leptin is elevated in MS patients but downregulated in AD, reflecting its bidirectional effects. In leptin resistance, peripheral proinflammatory signaling is maintained while central leptin signaling is restricted, thereby potentially promoting autoimmunity in MS and limiting neuroprotection in AD. Further mechanistic and longitudinal studies are needed to clarify the relationship between leptin dysregulation, leptin resistance, neuroinflammatory and neurodegenerative diseases.

Indexed as

Alzheimer DiseaseLeptinMultiple SclerosisNeuroinflammatory DiseasesAnimalsHumansInflammationLeptinAlzheimer’s diseaseimmune regulationleptinleptin resistancemultiple sclerosisneurodegenerative diseasesneuroinflammatory diseases

Identifiers

PMID41516046
PMCPMC12785794

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.